PCSK9 and resistin at the crossroads of the atherogenic dyslipidemia

Expert Review of Cardiovascular Therapy

Volumn 11, Issue 11, 2013, Pages 1567-1577

  Rashid, Shirya ^a   Kastelein, John J P ^b  

^a MCMASTER UNIVERSITY   (Canada)

^b UNIVERSITY OF AMSTERDAM   (Netherlands)

Author keywords

atherogenic dyslipidemia; atherosclerotic cardiovascular diseases; PCSK9; resistin; triglycerides; VLDL

Indexed keywords

ADENOVIRUS VECTOR; ANTISENSE OLIGONUCLEOTIDE; CELL PROTEIN; CHOLESTEROL ESTER TRANSFER PROTEIN; EZETIMIBE; FIBRIC ACID DERIVATIVE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; LIPOPROTEIN LIPASE; LIVER PROTEIN; LOMITAPIDE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN RECEPTOR; MONOCLONAL ANTIBODY; NICOTINIC ACID; OMEGA 3 FATTY ACID; PCSK9 MONOCLONAL ANTIBODY; PCSK9 PROTEIN; RESISTIN; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; VERY LOW DENSITY LIPOPROTEIN;

ABSENCE OF SIDE EFFECTS; ANTISENSE THERAPY; ATHEROGENESIS; ATHEROGENIC DYSLIPIDEMIA; ATHEROSCLEROTIC CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; DISEASE COURSE; DRUG EFFICACY; DRUG SAFETY; DYSLIPIDEMIA; FAMILIAL HYPERCHOLESTEROLEMIA; FATTY LIVER; GAIN OF FUNCTION MUTATION; GASTROINTESTINAL SYMPTOM; GENE DELETION; GENE EXPRESSION; GENE SILENCING; GENE THERAPY; GENETIC REGULATION; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTRIGLYCERIDEMIA; INSULIN RESISTANCE; LIPID METABOLISM; LIPOPROTEIN LIPASE GENE; META ANALYSIS (TOPIC); MISSENSE MUTATION; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; PHASE 2 CLINICAL TRIAL (TOPIC); REVIEW; RISK REDUCTION; TRIACYLGLYCEROL BLOOD LEVEL;

ANIMALS; APOLIPOPROTEINS B; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASES; DISEASE PROGRESSION; DYSLIPIDEMIAS; HUMANS; LIPOPROTEINS, VLDL; LIVER; PROPROTEIN CONVERTASES; RESISTIN; RISK FACTORS; SERINE ENDOPEPTIDASES;

EID: 84887376318     PISSN: 14779072     EISSN: 17448344     Source Type: Journal    
DOI: 10.1586/14779072.2013.839204     Document Type: Review

References (78)

1. Flegal KM, Carroll MD, Kit BK, Ogden CL. Prevalence of obesity and trends in the distribution of body mass index among US adults, 1999-2010. JAMA 307(5), 491-497 (2012
2. Runge CF. Economic consequences of the obese. Diabetes 56(11), 2668-2672 (2007
3. Grundy SM. Obesity, metabolic syndrome, and cardiovascular disease. J. Clin. Endocrinol. Metab. 89(6), 2595-2600 (2004
4. Despres JP, Lemieux I. Abdominal obesity and metabolic syndrome. Nature 444(7121), 881-887 (2006
5. Yusuf S, Hawken S, Ounpuu S et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): Case-control study. Lancet 364(9438), 937-952 (2004
6. Fox CS, Massaro JM, Hoffmann U et al. Abdominal visceral and subcutaneous adipose tissue compartments: Association with metabolic risk factors in the Framingham Heart Study. Circulation 116(1), 39-48 (2007
7. Despres JP. Cardiovascular disease under the influence of excess visceral fat. Crit. Pathw. Cardiol. 6(2), 51-59 (2007
8. Franssen R, Monajemi H, Stroes ES, Kastelein JJ. Obesity and dyslipidemia. Med. Clin. North Am. 95(5), 893-902 (2011
9. Boekholdt SM, Arsenault BJ, Mora S et al. Association of LDL cholesterol, non-HDL cholesterol, and apolipoprotein B levels with risk of cardiovascular events among patients treated with statins: A meta-Analysis. JAMA 307(12), 1302-1309 (2012).
10. Rana JS, Boekholdt SM, Kastelein JJ, Shah PK. The role of non-HDL cholesterol in risk stratification for coronary artery disease. Curr. Atheroscler. Rep. 14(2), 130-134 (2012
11. Adiels M, Olofsson SO, Taskinen MR, Boren J. Overproduction of very low-density lipoproteins is the hallmark of the dyslipidemia in the metabolic syndrome. Arterioscler. Thromb. Vasc. Biol. 28(7), 1225-1236 (2008
12. Adiels M, Olofsson SO, Taskinen MR, Boren J. Diabetic dyslipidaemia. Curr. Opin. Lipidol. 17(3), 238-246 (2006
13. Taskinen MR. Diabetic dyslipidaemia: From basic research to clinical practice. Diabetologia 46(6), 733-749 (2003
14. de Grooth GJ, Smilde TJ, Van WS et al. The relationship between cholesteryl ester transfer protein levels and risk factor profile in patients with familial hypercholesterolemia. Atherosclerosis 173(2), 261-267 (2004
15. Bamba V, Rader DJ. Obesity and atherogenic dyslipidemia. Gastroenterology 132(6), 2181-2190 (2007
16. Sparks JD, Sparks CE, Adeli K. Selective hepatic insulin resistance, VLDL overproduction, and hypertriglyceridemia. Arterioscler. Thromb. Vasc. Biol. 32(9), 2104-2112 (2012
17. Tan GD, Olivecrona G, Vidal H, Frayn KN, Karpe F. Insulin sensitisation affects lipoprotein lipase transport in Type 2 diabetes: Role of adipose tissue and skeletal muscle in response to rosiglitazone. Diabetologia 49(10), 2412-2418 (2006
18. Cohn JS, Tremblay M, Batal R et al. Increased apoC-III production is a characteristic feature of patients with hypertriglyceridemia. Atherosclerosis 177(1), 137-145 (2004
19. Huang XS, Zhao SP, Hu M, Bai L, Zhang Q, Zhao W. Decreased apolipoprotein A5 is implicated in insulin resistance-related hypertriglyceridemia in obesity. Atherosclerosis 210(2), 563-568 (2010
20. Merkel M, Loeffler B, Kluger M et al. Apolipoprotein AV accelerates plasma hydrolysis of triglyceride-rich lipoproteins by interaction with proteoglycan-bound lipoprotein lipase. J. Biol. Chem. 280(22), 21553-21560 (2005
21. Abifadel M, Varret M, Rabes JP et al. Mutations in PCSK9 cause autosomal dominant hypercholesterolemia. Nat. Genet. 34(2), 154-156 (2003
22. Rashid S, Curtis DE, Garuti R et al. Decreased plasma cholesterol and hypersensitivity to statins in mice lacking Pcsk9. Proc. Natl Acad. Sci. USA 102(15), 5374-5379 (2005
23. Cohen JC, Boerwinkle E, Mosley TH Jr, Hobbs HH. Sequence variations in PCSK9, low LDL, and protection against coronary heart disease. N. Engl. J. Med. 354(12), 1264-1272 (2006
24. Ouguerram K, Chetiveaux M, Zair Y et al. Apolipoprotein B100 metabolism in autosomal-dominant hypercholesterolemia related to mutations in PCSK9. Arterioscler. Thromb. Vasc. Biol. 24(8), 1448-1453 (2004
25. Herbert B, Patel D, Waddington SN et al. Increased secretion of lipoproteins in transgenic mice expressing human D374Y PCSK9 under physiological genetic control. Arterioscler. Thromb. Vasc. Biol. 30(7), 1333-1339 (2010
26. Lakoski SG, Lagace TA, Cohen JC, Horton JD, Hobbs HH. Genetic and metabolic determinants of plasma PCSK9 levels. J. Clin. Endocrinol. Metab. 94(7), 2537-2543 (2009
27. Baass A, Dubuc G, Tremblay M et al. Plasma PCSK9 is associated with age, sex, and multiple metabolic markers in a population-based sample of children and adolescents. Clin. Chem. 55(9), 1637-1645 (2009
28. Cariou B, Langhi C, Le BM et al. Plasma PCSK9 concentrations during an oral fat load and after short term high-fat, high-fat high-protein and high-fructose diets. Nutr. Metab. (Lond). 10(1), 4-10 (2013
29. Maxwell KN, Breslow JL. Adenoviral-mediated expression of Pcsk9 in mice results in a low-density lipoprotein receptor knockout phenotype. Proc. Natl Acad. Sci. USA 101(18), 7100-7105 (2004
30. Park SW, Moon YA, Horton JD. Post-Transcriptional regulation of low density lipoprotein receptor protein by proprotein convertase subtilisin/kexin type 9a in mouse liver. J. Biol. Chem. 279(48), 50630-50638 (2004
31. Lambert G, Jarnoux AL, Pineau T et al. Fasting induces hyperlipidemia in mice overexpressing proprotein convertase subtilisin kexin type 9: Lack of modulation of very-low-density lipoprotein hepatic output by the low-density lipoprotein receptor. Endocrinology 147(10), 4985-4995 (2006
32. Sun H, Samarghandi A, Zhang N, Yao Z, Xiong M, Teng BB. Proprotein convertase subtilisin/kexin type 9 interacts with apolipoprotein B and prevents its intracellular degradation, irrespective of the low-density lipoprotein receptor. Arterioscler. Thromb. Vasc. Biol. 32(7), 1585-1595 (2012
33. Gillian-Daniel DL, Bates PW, Tebon A, Attie AD. Endoplasmic reticulum localization of the low density lipoprotein receptor mediates presecretory degradation of apolipoprotein B. Proc. Natl Acad. Sci. USA 99(7), 4337-4342 (2002
34. Blasiole DA, Oler AT, Attie AD. Regulation of ApoB secretion by the low density lipoprotein receptor requires exit from the endoplasmic reticulum and interaction with ApoE or ApoB. J. Biol. Chem. 283(17), 11374-11381 (2008
35. Soutar AK. Unexpected roles for PCSK9 in lipid metabolism. Curr. Opin. Lipidol. 22(3), 192-196 (2011
36. Browning JD, Horton JD. Fasting reduces plasma proprotein convertase, subtilisin/ kexin type 9 and cholesterol biosynthesis in humans. J. Lipid Res. 51(11), 3359-3363 (2010
37. Ai D, Chen C, Han S et al. Regulation of hepatic LDL receptors by mTORC1 and PCSK9 in mice. J. Clin. Invest. 122(4), 1262-1270 (2012
38. Steppan CM, Bailey ST, Bhat S et al. The hormone resistin links obesity to diabetes. Nature 409(6818), 307-312 (2001
39. Steppan CM, Brown EJ, Wright CM et al. A family of tissue-specific resistin-like molecules. Proc. Natl Acad. Sci. USA 98(2), 502-506 (2001
40. Qatanani M, Szwergold NR, Greaves DR, Ahima RS, Lazar MA. Macrophage-derived human resistin exacerbates adipose tissue inflammation and insulin resistance in mice. J. Clin. Invest. 119(3), 531-539 (2009
41. Degawa-Yamauchi M, Bovenkerk JE, Juliar BE et al. Serum resistin (FIZZ3) protein is increased in obese humans. J. Clin. Endocrinol. Metab. 88(11), 5452-5455 (2003
42. Vendrell J, Broch M, Vilarrasa N et al. Resistin, adiponectin, ghrelin, leptin, and proinflammatory cytokines: Relationships in obesity. Obes. Res. 12(6), 962-971 (2004
43. Schaffler A, Buchler C, Muller-Ladner U et al. Identification of variables influencing resistin serum levels in patients with Type 1 and Type 2 diabetes mellitus. Horm. Metab. Res. 36(10), 702-707 (2004
44. Azuma K, Katsukawa F, Oguchi S et al. Correlation between serum resistin level and adiposity in obese individuals. Obes. Res. 11(8), 997-1001 (2003
45. Piestrzeniewicz K, Luczak K, Komorowski J, Maciejewski M, Jankiewicz WJ, Goch JH. Resistin increases with obesity and atherosclerotic risk factors in patients with myocardial infarction. Metabolism 57(4), 488-493 (2008
46. Vozarova de Court, Degawa-Yamauchi M, Considine RV, Tataranni PA. High serum resistin is associated with an increase in adiposity but not a worsening of insulin resistance in Pima Indians. Diabetes 53(5), 1279-1284 (2004
47. Yannakoulia M, Yiannakouris N, Bluher S, Matalas AL, Klimis-Zacas D, Mantzoros CS. Body fat mass and macronutrient intake in relation to circulating soluble leptin receptor, free leptin index, adiponectin, and resistin concentrations in healthy humans. J. Clin. Endocrinol. Metab. 88(4), 1730-1736 (2003
48. Reilly MP, Lehrke M, Wolfe ML, Rohatgi A, Lazar MA, Rader DJ. Resistin is an inflammatory marker of atherosclerosis in humans. Circulation 111(7), 932-939 (2005
49. Norata GD, Ongari M, Garlaschelli K, Raselli S, Grigore L, Catapano AL. Plasma resistin levels correlate with determinants of the metabolic syndrome. Eur. J. Endocrinol. 156(2), 279-284 (2007
50. Costandi J, Melone M, Zhao A, Rashid S. Human resistin stimulates hepatic overproduction of atherogenic ApoB-containing lipoprotein particles by enhancing ApoB stability and impairing intracellular insulin signaling. Circ. Res. 108(6), 727-742 (2011
51. Adeli K, Taghibiglou C, Van Iderstine SC, Lewis GF. Mechanisms of hepatic very low-density lipoprotein overproduction in insulin resistance. Trends Cardiovasc. Med. 11(5), 170-176 (2001
52. Melone M, Wilsie L, Palyha O, Strack A, Rashid S. Discovery of a new role of human resistin in hepatocyte low-density lipoprotein receptor suppression mediated in part by proprotein convertase subtilisin/ kexin type 9. J. Am. Coll. Cardiol. 59(19), 1697-1705 (2012
53. Fazio S, Linton MF. Proprotein convertase subtilisin/kexin type 9 as transducer of physiologic influences on cellular cholesterol: A case for resistin. J. Am. Coll. Cardiol. 59(19), 1706-1708 (2012
54. Chapman MJ, Ginsberg HN, Amarenco P et al. Triglyceride-rich lipoproteins and high-density lipoprotein cholesterol in patients at high risk of cardiovascular disease: Evidence and guidance for management. Eur. Heart J. 32(11), 1345-1361 (2011
55. Fruchart JC, Sacks F, Hermans MP et al. The Residual Risk Reduction Initiative: A call to action to reduce residual vascular risk in patients with dyslipidemia. Am. J. Cardiol. 102(10 Suppl.), 1K-34K (2008
56. Boden WE, Probstfield JL, Anderson T et al. Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. N. Engl. J. Med. 365(24), 2255-2267 (2011
57. Matikainen N, Taskinen MR. Management of dyslipidemias in the presence of the metabolic syndrome or Type 2 diabetes. Curr. Cardiol. Rep. 14(6), 721-731 (2012
58. Wierzbicki AS, Clarke RE, Viljoen A, Mikhailidis DP. Triglycerides: A case for treatment? Curr. Opin. Cardiol. 27(4), 398-404 (2012
59. Konig A, Bouzan C, Cohen JT et al. A quantitative analysis of fish consumption and coronary heart disease mortality. Am. J. Prev. Med. 29(4), 335-346 (2005
60. Bays HE, Ballantyne CM, Kastelein JJ, Isaacsohn JL, Braeckman RA, Soni PN. Eicosapentaenoic acid ethyl ester (AMR101) therapy in patients with very high triglyceride levels (from the Multi-center, plAcebo-controlled, Randomized, double-blINd, 12-week study with an open-label Extension [MARINE] trial). Am. J. Cardiol. 108(5), 682-690 (2011
61. Ballantyne CM, Bays HE, Kastelein JJ et al. Efficacy and safety of eicosapentaenoic acid ethyl ester (AMR101) therapy in statin-Treated patients with persistent high triglycerides (from the ANCHOR study). Am. J. Cardiol. 110(7), 984-992 (2012
62. Graham MJ, Lee RG, Bell TA, III et al. Antisense oligonucleotide inhibition of apolipoprotein C-III reduces plasma triglycerides in rodents, nonhuman primates, and humans. Circ. Res. 112(11), 1479-1490 (2013
63. Gaudet D, Methot J, Kastelein J. Gene therapy for lipoprotein lipase deficiency. Curr. Opin. Lipidol. 23(4), 310-320 (2012
64. Cuchel M, Rader DJ. Microsomal transfer protein inhibition in humans. Curr. Opin. Lipidol. 24(3), 246-250 (2013
65. Costet P, Hoffmann MM, Cariou B, Guyomarch DB, Konrad T, Winkler K. Plasma PCSK9 is increased by fenofibrate and atorvastatin in a non-Additive fashion in diabetic patients. Atherosclerosis 212(1), 246-251 (2010
66. Roth EM, McKenney JM, Hanotin C, Asset G, Stein EA. Atorvastatin with or without an antibody to PCSK9 in primary hypercholesterolemia. N. Engl. J. Med. 367(20), 1891-1900 (2012
67. Giugliano RP, Desai NR, Kohli P et al. Efficacy, safety, and tolerability of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 in combination with a statin in patients with hypercholesterolaemia (LAPLACE-TIMI 57): A randomised, placebo-controlled, dose-ranging, phase 2 study. Lancet 380(9858), 2007-2017 (2012
68. King A. Lipids. Antibodies against PCSK9-A new era of therapy. Nat. Rev. Cardiol. 10(1), 1 (2013
69. Farnier M. PCSK9 inhibitors. Curr. Opin. Lipidol. 24(3), 251-258 (2013
70. Hooper AJ, Burnett Jr. Anti-PCSK9 therapies for the treatment of hypercholesterolemia. Expert Opin. Biol. Ther. 13(3), 429-435 (2013
71. Duff CJ, Hooper NM. PCSK9: An emerging target for treatment of hypercholesterolemia. Expert Opin. Ther. Targets 15(2), 157-168 (2011
72. Visser ME, Witztum JL, Stroes ES, Kastelein JJ. Antisense oligonucleotides for the treatment of dyslipidaemia. Eur. Heart J. 33(12), 1451-1458 (2012
73. Lindholm MW, Elmen J, Fisker N et al. PCSK9 LNA antisense oligonucleotides induce sustained reduction of LDL cholesterol in nonhuman primates. Mol. Ther. 20(2), 376-381 (2012
74. Gupta N, Fisker N, Asselin MC et al. A locked nucleic acid antisense oligonucleotide (LNA) silences PCSK9 and enhances LDLR expression in vitro and in vivo. PLoS ONE 5(5), e10682 (2010
75. Frank-Kamenetsky M, Grefhorst A, Anderson NN et al. Therapeutic RNAi targeting PCSK9 acutely lowers plasma cholesterol in rodents and LDL cholesterol in nonhuman primates. Proc. Natl Acad. Sci. USA 105(33), 11915-11920 (2008
76. Daquinag AC, Zhang Y, Amaya-Manzanares F, Simmons PJ, Kolonin MG. An isoform of decorin is a resistin receptor on the surface of adipose progenitor cells. Cell Stem Cell. 9(1), 74-86 (2011
77. Miller M, Cannon CP, Murphy SA, Qin J, Ray KK, Braunwald E. Impact of triglyceride levels beyond low-density lipoprotein cholesterol after acute coronary syndrome in the PROVE IT-TIMI 22 trial. J. Am.Coll.Cardiol. 51(7), 724-730 (2008
78. Sarwar N, Danesh J, Eiriksdottir G et al. Triglycerides and the risk of coronary heart disease: 10,158 incident cases among 262,525 participants in 29 Western prospective studies. Circulation 115(4), 450-458 (2007